坤泰胶囊联合替勃龙治疗围绝经期综合征的临床观察

Clinical observation of Kuntai Capsule combined with tibolone in treatment of perimenopausal syndrome

目的探讨坤泰胶囊联合替勃龙治疗围绝经期综合征的临床疗效。方法选取2019年10月—2021年3月合肥市第八人民医院收治的80例围绝经期综合征妇女作为研究对象,进行回顾性研究。根据治疗方法将患者分为对照组和试验组,每组40例。对照组患者均给予口服替勃龙治疗,每次1.25 mg,每天1次;试验组患者在对照组基础上联合口服坤泰胶囊治疗,每次2.0 g,每天3次,两组疗程均为3个月。测定并记录两组患者治疗前后的性激素水平及子宫内膜厚度,采用改良Kupperman Index量表(KI)对两组治疗前后的临床症状进行评分,以患者治疗前后KI评分改善程度为依据评价两组临床治疗效果,统计并比较两组患者不良反应发生情况。结果试验组患者治疗后的黄体生成素(LH)、促卵泡激素(FSH)水平均较治疗前及对照组治疗后明显降低(P<0.05),雌二醇(E_(2))水平均较治疗前及对照组治疗后明显升高(P<0.05);两组患者治疗前后及组间的子宫内膜厚度差异均无统计学意义(P>0.05),但两组治疗后的KI评分均较治疗前明显降低(P<0.05);试验组患者临床总有效率92.50%略高于对照组的87.50%,但差异无统计学意义(P>0.05);试验组患者临床不良反应发生率7.50%明显低于对照组的25.00%,差异具有统计学意义(P<0.05)。结论在替勃龙治疗基础上加用坤泰胶囊,可有效改善围绝经期综合征患者的临床症状及性激素水平,减少不良反应的发生,其疗效确切且用药安全性高。

Objective To investigate the clinical efficacy of Kuntai Capsule combined with tibolone in the treatment of perimenopausal syndrome.Methods A retrospective study was conducted on 80 women with perimenopausal syndrome treated in Hefei Eighth People's Hospital from October 2019 to March 2021.According to the treatment methods,the patients were divided into control group and experimental group,with 40 cases in each group.The patients in the control group were treated with oral tibolone,1.25 mg each time,once a day.On the basis of the control group,the patients in the experimental group were treated with Kuntai Capsule,2.0 g each time,three times a day.The course of treatment of both groups was three months.The sex hormone levels and endometrial thickness of the two groups before and after treatment were measured and recorded.The clinical symptoms of the two groups before and after treatment were scored by the modified Kupperman Index(KI)scale.The clinical treatment effects of the two groups were evaluated based on the improvement of KI scores before and after treatment,and the adverse reactions of the two groups were counted and compared.Results The levels of luteinizing hormone(LH)and follicle stimulating hormone(FSH)in the experimental group were significantly lower than those before treatment and the control group at the same period(P<0.05),and the levels of estradiol(E_(2))were significantly higher than those before treatment and the control group at the same period(P<0.05).There was no significant difference in endometrial thickness between the two groups before and after treatment(P>0.05),but the KI score of the two groups after treatment was significantly lower than that before treatment(P<0.05).The total clinical effective rate in the experimental group was 92.50%,which was slightly higher than 87.50%in the control group,but the difference was not statistically significant(P>0.05).The incidence of clinical adverse reactions in the experimental group was 7.50%,which was significantly lower than 25.00%in the control group(P<0.05).Conclusion The use of Kuntai Capsule on the basis of tibolone treatment can effectively improve the clinical symptoms and sex hormone level of patients with perimenopausal syndrome,reduce the occurrence of adverse reactions,have definite curative effect and high drug safety.